

**Amendments to the Claims:**

Claims 1-9 (canceled)

10. (currently amended) A conjugate comprising ~~insulin-like growth factor binding protein-4~~ SEQ ID NO:2 and a constituent or constituents selected from the group consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa.

11. (currently amended) The conjugate according to claim 10 4, wherein the single poly(ethylene glycol) group is a branched poly(ethylene glycol) group.

12. (currently amended) The conjugate according to claim 10 4, wherein the two poly(ethylene glycol) groups are branched poly(ethylene glycol) groups.

13. (currently amended) The conjugate according to claim 10 4, wherein only one of the two poly(ethylene glycol) groups is a branched poly(ethylene glycol) group.

14. (currently amended) A conjugate according to claim 10 4 wherein ~~the conjugate~~ SEQ ID NO:2 is linked to one or two poly(ethylene glycol) groups by a ~~cysteine member~~ selected from the group consisting of: (1) cysteine 110; (2) cysteine 117; ~~or~~ and (3) cysteine 110 and cysteine 117 of SEQ ID NO:2.

15. (currently amended) A conjugate comprising ~~insulin-like growth factor binding protein-4~~ SEQ ID NO:2 and a constituent or constituents selected from the group

consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa, produced by a process comprising reacting the insulin-like growth factor binding protein-4 SEQ ID NO:2 with activated (polyethylene) glycol under conditions such that said (polyethylene) glycol is chemically bound to said insulin-like growth factor binding protein-4 SEQ ID NO:2 by primary amino groups or thiol groups of SEQ ID NO:2 insulin-like growth factor binding protein-4.

16. (currently amended) A pharmaceutical composition comprising the conjugate of claim 10 4 and a pharmaceutically acceptable carrier.

17. (currently amended) A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a conjugate comprising insulin-like growth factor binding protein-4 SEQ ID NO:2 and a constituent or constituents selected from the group consisting of: (1) a single poly(ethylene glycol) group having an overall molecular weight of from about 30 to about 40 kDa, and (2) two poly(ethylene glycol) groups having an overall molecular weight of from about 30 to about 40 kDa.